Story
Novo Nordisk Sues Eli Lilly, Alleging False Advertising for Weight-Loss Drugs

Novo Nordisk announced Tuesday it has filed a lawsuit against rival Eli Lilly in a U.S. federal court, accusing the American pharmaceutical giant of false advertising in the fiercely competitive weight-loss drug market. The suit alleges that Lilly's marketing campaigns for its popular treatments create a misleading impression of superior efficacy compared to Novo's products.
The Core Allegations
The lawsuit, filed in the U.S. District Court in New Jersey, claims that Eli Lilly has violated federal and state false advertising and unfair competition laws, including the Lanham Act. Novo Nordisk contends that nationwide advertising for Lilly's obesity drug Zepbound and diabetes treatment Mounjaro unfairly compares the highest approved doses of those medicines with lower, less effective doses of its own drugs, Wegovy and Ozempic.
According to Novo Nordisk, the ads omit newer, higher-dose versions of its treatments that it says deliver greater weight loss, thereby skewing the comparison. John Kuckelman, Novo's general counsel, told Reuters the company sent a cease-and-desist letter to Lilly in April, which went unanswered.
A Dispute Over Data
The central issue is the data used in Lilly's promotional materials. Novo Nordisk highlights a specific discrepancy in the advertised weight-loss figures:
Ad- Lilly's ads compare weight loss of about 50 pounds for Zepbound with about 33 pounds for Wegovy, according to the lawsuit.
- Novo Nordisk argues that separate late-stage trials of the highest approved doses of both drugs show much more comparable results: average weight loss of about 48 pounds for Zepbound and 47 pounds for Wegovy.
Kuckelman noted that no head-to-head clinical trial has directly compared the highest approved doses of the two medicines.
Legal Action and Market Context
Novo Nordisk is seeking a court order that would require Eli Lilly to withdraw the advertisements and fund a corrective advertising campaign. The company also stated it intends to seek a preliminary injunction if Lilly does not voluntarily remove the ads.
The legal battle underscores the intense rivalry between the two dominant players in the rapidly growing global market for GLP-1 agonist drugs. The success of these treatments for obesity and diabetes has propelled both companies to become two of the most valuable in the world, and market share is aggressively contested through both research and marketing.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.